{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T10:13:44Z","timestamp":1782900824474,"version":"3.54.5"},"reference-count":95,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,6,12]],"date-time":"2023-06-12T00:00:00Z","timestamp":1686528000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["jacc.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JACC: CardioOncology"],"published-print":{"date-parts":[[2023,8]]},"DOI":"10.1016\/j.jaccao.2023.05.008","type":"journal-article","created":{"date-parts":[[2023,7,11]],"date-time":"2023-07-11T14:06:46Z","timestamp":1689084406000},"page":"415-430","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":26,"title":["Cardiac Interventions in Patients With Active, Advanced Solid and Hematologic\u00a0Malignancies"],"prefix":"10.1016","volume":"5","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1968-169X","authenticated-orcid":false,"given":"Darryl P.","family":"Leong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Filipe","family":"Cirne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nazanin","family":"Aghel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rocio C.","family":"Baro Vila","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Germano D.","family":"Cavalli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter M.","family":"Ellis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeff S.","family":"Healey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Whitlock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dina","family":"Khalaf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hira","family":"Mian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanjit S.","family":"Jolly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shamir R.","family":"Mehta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"Dent","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.jaccao.2023.05.008_bib1","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1001\/jamaoncol.2014.161","article-title":"Disparities by race, age, and sex in the improvement of survival for major cancers: results from the National Cancer Institute Surveillance, Epidemiology, and End Results (SEER) Program in the United States, 1990 to 2010","volume":"1","author":"Zeng","year":"2015","journal-title":"JAMA Oncol"},{"issue":"9760","key":"10.1016\/j.jaccao.2023.05.008_bib2","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/S0140-6736(10)62231-3","article-title":"Cancer survival in Australia, Canada, Denmark, Norway, Sweden, and the UK, 1995-2007 (the International Cancer Benchmarking Partnership): an analysis of population-based cancer registry data","volume":"377","author":"Coleman","year":"2011","journal-title":"Lancet"},{"issue":"17","key":"10.1016\/j.jaccao.2023.05.008_bib3","doi-asserted-by":"crossref","first-page":"e263","DOI":"10.1016\/j.jacc.2021.12.012","article-title":"2022 AHA\/ACC\/HFSA guideline for the management of heart failure: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"79","author":"Heidenreich","year":"2022","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"2","key":"10.1016\/j.jaccao.2023.05.008_bib4","doi-asserted-by":"crossref","first-page":"e21","DOI":"10.1016\/j.jacc.2021.09.006","article-title":"2021 ACC\/AHA\/SCAI guideline for coronary artery revascularization: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"79","author":"Lawton","year":"2022","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"4","key":"10.1016\/j.jaccao.2023.05.008_bib5","doi-asserted-by":"crossref","first-page":"e25","DOI":"10.1016\/j.jacc.2020.11.018","article-title":"2020 ACC\/AHA guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"77","author":"Otto","year":"2021","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"14","key":"10.1016\/j.jaccao.2023.05.008_bib6","doi-asserted-by":"crossref","first-page":"e91","DOI":"10.1016\/j.jacc.2017.10.054","volume":"72","author":"Al-Khatib","year":"2018","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"4","key":"10.1016\/j.jaccao.2023.05.008_bib7","article-title":"Using the Zwolle Risk Score at time of coronary angiography to triage patients with ST-elevation myocardial infarction following primary percutaneous coronary intervention or thrombolysis","volume":"11","author":"Parr","year":"2022","journal-title":"J\u00a0Am Heart Assoc"},{"issue":"44","key":"10.1016\/j.jaccao.2023.05.008_bib8","doi-asserted-by":"crossref","first-page":"4536","DOI":"10.1093\/eurheartj\/ehab342","article-title":"Reperfusion therapies and in-hospital outcomes for ST-elevation myocardial infarction in Europe: the ACVC-EAPCI EORP STEMI Registry of the European Society of Cardiology","volume":"42","author":"Zeymer","year":"2021","journal-title":"Eur Heart J"},{"issue":"9351","key":"10.1016\/j.jaccao.2023.05.008_bib9","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/S0140-6736(03)12113-7","article-title":"Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review of 23 randomised trials","volume":"361","author":"Keeley","year":"2003","journal-title":"Lancet"},{"issue":"25","key":"10.1016\/j.jaccao.2023.05.008_bib10","doi-asserted-by":"crossref","first-page":"3789","DOI":"10.1161\/01.CIR.0000150392.70749.C7","article-title":"Predictors of quality-of-life benefit after percutaneous coronary intervention","volume":"110","author":"Spertus","year":"2004","journal-title":"Circulation"},{"issue":"1","key":"10.1016\/j.jaccao.2023.05.008_bib11","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.ejca.2011.09.015","article-title":"Risk of coronary heart disease in patients with cancer: a nationwide follow-up study from Sweden","volume":"48","author":"Zoller","year":"2012","journal-title":"Eur J Cancer"},{"issue":"15","key":"10.1016\/j.jaccao.2023.05.008_bib12","article-title":"Morphological plaque characteristics and clinical outcomes in patients with acute coronary syndrome and a cancer history","volume":"10","author":"Tanimura","year":"2021","journal-title":"J\u00a0Am Heart Assoc"},{"issue":"1","key":"10.1016\/j.jaccao.2023.05.008_bib13","first-page":"22","article-title":"Screening for coronary artery disease in cancer survivors","volume":"5","author":"Velusamy","year":"2023","journal-title":"J\u00a0Am Coll Cardiol CardioOnc"},{"issue":"2","key":"10.1016\/j.jaccao.2023.05.008_bib14","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1007\/s00432-015-2056-5","article-title":"Analysis of outcomes of percutaneous coronary intervention in metastatic cancer patients with acute coronary syndrome over a 10-year period","volume":"142","author":"Guddati","year":"2016","journal-title":"J\u00a0Cancer Res Clin Oncol"},{"issue":"15","key":"10.1016\/j.jaccao.2023.05.008_bib15","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1056\/NEJMoa1907775","article-title":"Complete revascularization with multivessel PCI for myocardial infarction","volume":"381","author":"Mehta","year":"2019","journal-title":"N\u00a0Engl J Med"},{"issue":"11","key":"10.1016\/j.jaccao.2023.05.008_bib16","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1001\/jamacardio.2022.3032","article-title":"Complete revascularization vs culprit lesion-only percutaneous coronary intervention for angina-related quality of life in patients with ST-segment elevation myocardial infarction: results from the COMPLETE randomized clinical trial","volume":"7","author":"Mehta","year":"2022","journal-title":"JAMA Cardiol"},{"issue":"23","key":"10.1016\/j.jaccao.2023.05.008_bib17","doi-asserted-by":"crossref","first-page":"2908","DOI":"10.1001\/jama.293.23.2908","article-title":"Routine vs selective invasive strategies in patients with acute coronary syndromes: a collaborative meta-analysis of randomized trials","volume":"293","author":"Mehta","year":"2005","journal-title":"JAMA"},{"issue":"21","key":"10.1016\/j.jaccao.2023.05.008_bib18","doi-asserted-by":"crossref","first-page":"2165","DOI":"10.1056\/NEJMoa0807986","article-title":"Early versus delayed invasive intervention in acute coronary syndromes","volume":"360","author":"Mehta","year":"2009","journal-title":"N\u00a0Engl J Med"},{"issue":"24","key":"10.1016\/j.jaccao.2023.05.008_bib19","doi-asserted-by":"crossref","first-page":"2741","DOI":"10.1161\/CIRCULATIONAHA.118.037152","article-title":"Early versus standard care invasive examination and treatment of patients with non-ST-segment elevation acute coronary syndrome","volume":"138","author":"Kofoed","year":"2018","journal-title":"Circulation"},{"issue":"18","key":"10.1016\/j.jaccao.2023.05.008_bib20","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1161\/CIRCULATIONAHA.122.061527","article-title":"Effects on mortality and major bleeding of radial versus femoral artery access for coronary angiography or percutaneous coronary intervention: meta-analysis of individual patient data from 7 multicenter randomized clinical trials","volume":"146","author":"Gargiulo","year":"2022","journal-title":"Circulation"},{"issue":"9","key":"10.1016\/j.jaccao.2023.05.008_bib21","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1002\/clc.22702","article-title":"Breast arterial calcification association with coronary artery calcium scoring and implications for cardiovascular risk assessment in women","volume":"40","author":"Ryan","year":"2017","journal-title":"Clin Cardiol"},{"issue":"10318","key":"10.1016\/j.jaccao.2023.05.008_bib22","doi-asserted-by":"crossref","first-page":"2247","DOI":"10.1016\/S0140-6736(21)02334-5","article-title":"Percutaneous coronary intervention with drug-eluting stents versus coronary artery bypass grafting in left main coronary artery disease: an individual patient data meta-analysis","volume":"398","author":"Sabatine","year":"2021","journal-title":"Lancet"},{"issue":"15","key":"10.1016\/j.jaccao.2023.05.008_bib23","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1056\/NEJMoa070829","article-title":"Optimal medical therapy with or without PCI for stable coronary disease","volume":"356","author":"Boden","year":"2007","journal-title":"N\u00a0Engl J Med"},{"issue":"15","key":"10.1016\/j.jaccao.2023.05.008_bib24","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1056\/NEJMoa1915922","article-title":"Initial invasive or conservative strategy for stable coronary disease","volume":"382","author":"Maron","year":"2020","journal-title":"N\u00a0Engl J Med"},{"issue":"15","key":"10.1016\/j.jaccao.2023.05.008_bib25","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1056\/NEJMoa1916370","article-title":"Health-status outcomes with invasive or conservative care in coronary disease","volume":"382","author":"Spertus","year":"2020","journal-title":"N\u00a0Engl J Med"},{"issue":"10124","key":"10.1016\/j.jaccao.2023.05.008_bib26","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1016\/S0140-6736(18)30423-9","article-title":"Mortality after coronary artery bypass grafting versus percutaneous coronary intervention with stenting for coronary artery disease: a pooled analysis of individual patient data","volume":"391","author":"Head","year":"2018","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.jaccao.2023.05.008_bib27","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.jcin.2023.01.003","article-title":"Outcomes of medical therapy plus PCI for multivessel or left main CAD ineligible for surgery","volume":"16","author":"Salisbury","year":"2023","journal-title":"J\u00a0Am Coll Cardiol Intv"},{"key":"10.1016\/j.jaccao.2023.05.008_bib28","doi-asserted-by":"crossref","DOI":"10.1177\/20406223221093758","article-title":"Non-inferiority of 1\u00a0month versus longer dual antiplatelet therapy in patients undergoing PCI with drug-eluting stents: a systematic review and meta-analysis of randomized clinical trials","volume":"13","author":"Bajraktari","year":"2022","journal-title":"Ther Adv Chronic Dis"},{"issue":"3","key":"10.1016\/j.jaccao.2023.05.008_bib29","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/j.jcin.2021.11.028","article-title":"Short duration of DAPT versus de-escalation after percutaneous coronary intervention for acute coronary syndromes","volume":"15","author":"Laudani","year":"2022","journal-title":"J\u00a0Am Coll Cardiol Intv"},{"issue":"1","key":"10.1016\/j.jaccao.2023.05.008_bib30","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1186\/s12885-019-5354-5","article-title":"Risk and consequences of chemotherapy-induced thrombocytopenia in US clinical practice","volume":"19","author":"Weycker","year":"2019","journal-title":"BMC Cancer"},{"issue":"2","key":"10.1016\/j.jaccao.2023.05.008_bib31","first-page":"221","article-title":"Indications for platelet transfusion in patients with thrombocytopenia","volume":"13","author":"Squires","year":"2015","journal-title":"Blood Transfus"},{"key":"10.1016\/j.jaccao.2023.05.008_bib32","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.critrevonc.2018.09.014","article-title":"Antithrombotic medication in cancer-associated thrombocytopenia: current evidence and knowledge gaps","volume":"132","author":"Leader","year":"2018","journal-title":"Crit Rev Oncol Hematol"},{"issue":"10","key":"10.1016\/j.jaccao.2023.05.008_bib33","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1016\/j.jcin.2021.03.049","article-title":"Cancer patients have a higher risk of thrombotic and ischemic events after percutaneous coronary intervention","volume":"14","author":"Guo","year":"2021","journal-title":"J\u00a0Am Coll Cardiol Intv"},{"issue":"11","key":"10.1016\/j.jaccao.2023.05.008_bib34","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1056\/NEJMoa0904327","article-title":"Ticagrelor versus clopidogrel in patients with acute coronary syndromes","volume":"361","author":"Wallentin","year":"2009","journal-title":"N\u00a0Engl J Med"},{"issue":"20","key":"10.1016\/j.jaccao.2023.05.008_bib35","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1056\/NEJMoa0706482","article-title":"Prasugrel versus clopidogrel in patients with acute coronary syndromes","volume":"357","author":"Wiviott","year":"2007","journal-title":"N\u00a0Engl J Med"},{"issue":"6","key":"10.1016\/j.jaccao.2023.05.008_bib36","first-page":"E778","article-title":"A\u00a0systematic review and meta-analysis of impact of baseline thrombocytopenia on cardiovascular outcomes and mortality in patients undergoing percutaneous coronary intervention","volume":"97","author":"Ahsan","year":"2021","journal-title":"Catheter Cardiovasc Interv"},{"key":"10.1016\/j.jaccao.2023.05.008_bib37","doi-asserted-by":"crossref","unstructured":"Galimzhanov A, Sabitov Y, Tenekecioglu E, Tun HN, Alasnag M, Mamas MA. Baseline platelet count in percutaneous coronary intervention: a dose-response meta-analysis. Heart. https:\/\/doi.org\/10.1136\/heartjnl-2022-320910.","DOI":"10.1136\/heartjnl-2022-320910"},{"issue":"18","key":"10.1016\/j.jaccao.2023.05.008_bib38","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1056\/NEJMoa2108749","article-title":"Dual antiplatelet therapy after PCI in patients at high bleeding risk","volume":"385","author":"Valgimigli","year":"2021","journal-title":"N\u00a0Engl J Med"},{"issue":"6","key":"10.1016\/j.jaccao.2023.05.008_bib39","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/j.jacc.2022.11.041","article-title":"P2Y(12) inhibitor monotherapy or dual antiplatelet therapy after complex percutaneous coronary interventions","volume":"81","author":"Gragnano","year":"2023","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"5","key":"10.1016\/j.jaccao.2023.05.008_bib40","first-page":"895","volume":"87","author":"Iliescu","year":"2016","journal-title":"Catheter Cardiovasc Interv"},{"issue":"47","key":"10.1016\/j.jaccao.2023.05.008_bib41","doi-asserted-by":"crossref","first-page":"3488","DOI":"10.1093\/eurheartj\/ehx531","article-title":"The management of antiplatelet therapy in acute coronary syndrome patients with thrombocytopenia: a clinical conundrum","volume":"38","author":"McCarthy","year":"2017","journal-title":"Eur Heart J"},{"issue":"17","key":"10.1016\/j.jaccao.2023.05.008_bib42","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1056\/NEJMoa1008232","article-title":"Transcatheter aortic-valve implantation for aortic stenosis in patients who cannot undergo surgery","volume":"363","author":"Leon","year":"2010","journal-title":"N\u00a0Engl J Med"},{"issue":"14","key":"10.1016\/j.jaccao.2023.05.008_bib43","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1056\/NEJMoa0910383","article-title":"Adjuvant trastuzumab in HER2-positive breast cancer","volume":"365","author":"Slamon","year":"2011","journal-title":"N\u00a0Engl J Med"},{"issue":"4","key":"10.1016\/j.jaccao.2023.05.008_bib44","first-page":"544.e1","article-title":"Reversible cabozantinib-induced cardiomyopathy","volume":"35","author":"Alhussein","year":"2019","journal-title":"Can J Cardiol"},{"issue":"4","key":"10.1016\/j.jaccao.2023.05.008_bib45","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/0002-8703(81)90096-X","article-title":"Dose-effect and structure-function relationships in doxorubicin cardiomyopathy","volume":"102","author":"Bristow","year":"1981","journal-title":"Am Heart J"},{"issue":"11","key":"10.1016\/j.jaccao.2023.05.008_bib46","doi-asserted-by":"crossref","first-page":"2869","DOI":"10.1002\/cncr.11407","article-title":"Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials","volume":"97","author":"Swain","year":"2003","journal-title":"Cancer"},{"issue":"5","key":"10.1016\/j.jaccao.2023.05.008_bib47","doi-asserted-by":"crossref","first-page":"710","DOI":"10.7326\/0003-4819-91-5-710","article-title":"Risk factors for doxorubicin-induced congestive heart failure","volume":"91","author":"Von Hoff","year":"1979","journal-title":"Ann Intern Med"},{"issue":"3","key":"10.1016\/j.jaccao.2023.05.008_bib48","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1056\/NEJMoa043399","article-title":"Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure","volume":"352","author":"Bardy","year":"2005","journal-title":"N\u00a0Engl J Med"},{"issue":"12","key":"10.1016\/j.jaccao.2023.05.008_bib49","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1056\/NEJMoa013474","article-title":"Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction","volume":"346","author":"Moss","year":"2002","journal-title":"N\u00a0Engl J Med"},{"issue":"11","key":"10.1016\/j.jaccao.2023.05.008_bib50","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1161\/01.CIR.101.11.1297","article-title":"Canadian implantable defibrillator study (CIDS): a randomized trial of the implantable cardioverter defibrillator against amiodarone","volume":"101","author":"Connolly","year":"2000","journal-title":"Circulation"},{"issue":"25","key":"10.1016\/j.jaccao.2023.05.008_bib51","doi-asserted-by":"crossref","first-page":"1882","DOI":"10.1056\/NEJM199912163412503","article-title":"A\u00a0randomized study of the prevention of sudden death in patients with coronary artery disease. Multicenter Unsustained Tachycardia Trial Investigators","volume":"341","author":"Buxton","year":"1999","journal-title":"N\u00a0Engl J Med"},{"issue":"8","key":"10.1016\/j.jaccao.2023.05.008_bib52","first-page":"1024","article-title":"Guideline-directed medical therapy and the risk of death in primary prevention defibrillator recipients","volume":"8","author":"Dhande","year":"2022","journal-title":"J\u00a0Am Coll Cardiol EP"},{"issue":"15","key":"10.1016\/j.jaccao.2023.05.008_bib53","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1056\/NEJMoa050496","article-title":"The effect of cardiac resynchronization on morbidity and mortality in heart failure","volume":"352","author":"Cleland","year":"2005","journal-title":"N\u00a0Engl J Med"},{"issue":"3","key":"10.1016\/j.jaccao.2023.05.008_bib54","first-page":"447","article-title":"How to manage patients with cardiac implantable electronic devices undergoing radiation therapy","volume":"3","author":"Fradley","year":"2021","journal-title":"J\u00a0Am Coll Cardiol CardioOnc"},{"issue":"10","key":"10.1016\/j.jaccao.2023.05.008_bib55","doi-asserted-by":"crossref","first-page":"2148","DOI":"10.1016\/j.hrthm.2015.06.003","article-title":"Management of patients with implantable cardioverter-defibrillators and pacemakers who require radiation therapy","volume":"12","author":"Brambatti","year":"2015","journal-title":"Heart Rhythm"},{"issue":"1","key":"10.1016\/j.jaccao.2023.05.008_bib56","doi-asserted-by":"crossref","DOI":"10.1111\/eci.13862","article-title":"A\u00a0systematic review and meta-analysis on oncological radiotherapy in patients with a cardiac implantable electronic device: prevalence and predictors of device malfunction in 3121 patients","volume":"53","author":"Malavasi","year":"2023","journal-title":"Eur J Clin Invest"},{"issue":"9974","key":"10.1016\/j.jaccao.2023.05.008_bib57","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1016\/S0140-6736(14)61396-9","article-title":"40-year trends in an index of survival for all cancers combined and survival adjusted for age and sex for each cancer in England and Wales, 1971-2011: a population-based study","volume":"385","author":"Quaresma","year":"2015","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.jaccao.2023.05.008_bib58","first-page":"7","article-title":"Cancer statistics, 2022","volume":"72","author":"Siegel","year":"2022","journal-title":"CA Cancer J Clin"},{"issue":"9","key":"10.1016\/j.jaccao.2023.05.008_bib59","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1007\/s12094-019-02047-5","article-title":"Cardiovascular disease and survival in non-small cell lung cancer: a multicenter prospective assessment","volume":"21","author":"Herrero Rivera","year":"2019","journal-title":"Clin Transl Oncol"},{"issue":"2","key":"10.1016\/j.jaccao.2023.05.008_bib60","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1177\/1756287215617872","article-title":"Androgen deprivation therapy and cardiovascular disease: what is the linking mechanism?","volume":"8","author":"Zareba","year":"2016","journal-title":"Ther Adv Urol"},{"issue":"6","key":"10.1016\/j.jaccao.2023.05.008_bib61","first-page":"1109","article-title":"Cardiovascular risk in men with prostate cancer: insights from the RADICAL PC study","volume":"203","author":"Leong","year":"2020","journal-title":"J\u00a0Urol"},{"issue":"1","key":"10.1016\/j.jaccao.2023.05.008_bib62","first-page":"70","article-title":"The burden of uncontrolled cardiovascular risk factors in men with prostate cancer: a RADICAL-PC analysis","volume":"5","author":"Klimis","year":"2023","journal-title":"J\u00a0Am Coll Cardiol CardioOnc"},{"issue":"16","key":"10.1016\/j.jaccao.2023.05.008_bib63","doi-asserted-by":"crossref","first-page":"2895","DOI":"10.1002\/cncr.33584","article-title":"Cause of death during prostate cancer survivorship: a contemporary, US population-based analysis","volume":"127","author":"Weiner","year":"2021","journal-title":"Cancer"},{"issue":"4","key":"10.1016\/j.jaccao.2023.05.008_bib64","doi-asserted-by":"crossref","first-page":"pky062","DOI":"10.1093\/jncics\/pky062","article-title":"Change in survival in metastatic breast cancer with treatment advances: meta-analysis and systematic review","volume":"2","author":"Caswell-Jin","year":"2018","journal-title":"JNCI Cancer Spectr"},{"issue":"1","key":"10.1016\/j.jaccao.2023.05.008_bib65","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1097\/EDE.0000000000000394","article-title":"Cardiovascular disease mortality among breast cancer survivors","volume":"27","author":"Bradshaw","year":"2016","journal-title":"Epidemiology"},{"issue":"15","key":"10.1016\/j.jaccao.2023.05.008_bib66","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1200\/JCO.21.01736","article-title":"Risk of cardiovascular disease in women with and without breast cancer: the Pathways Heart study","volume":"40","author":"Greenlee","year":"2022","journal-title":"J\u00a0Clin Oncol"},{"issue":"2","key":"10.1016\/j.jaccao.2023.05.008_bib67","first-page":"149","article-title":"Cardiometabolic comorbidities in cancer survivors: JACC: CardioOncology state-of-the-art review","volume":"4","author":"Zullig","year":"2022","journal-title":"J\u00a0Am Coll Cardiol CardioOnc"},{"issue":"3","key":"10.1016\/j.jaccao.2023.05.008_bib68","article-title":"Accumulation of deficits as a key risk factor for cardiovascular morbidity and mortality: a pooled analysis of 154 000 individuals","volume":"9","author":"Farooqi","year":"2020","journal-title":"J\u00a0Am Heart Assoc"},{"issue":"19","key":"10.1016\/j.jaccao.2023.05.008_bib69","doi-asserted-by":"crossref","first-page":"1998","DOI":"10.1001\/jama.2014.3741","article-title":"Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs","volume":"311","author":"Kris","year":"2014","journal-title":"JAMA"},{"issue":"14","key":"10.1016\/j.jaccao.2023.05.008_bib70","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1200\/JCO.19.03136","article-title":"Updated analysis from KEYNOTE-189: pembrolizumab or placebo plus pemetrexed and platinum for previously untreated metastatic nonsquamous non-small-cell lung cancer","volume":"38","author":"Gadgeel","year":"2020","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jaccao.2023.05.008_bib71","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.lungcan.2017.05.021","article-title":"Treatment outcomes by histology in REVEL: a randomized phase III trial of ramucirumab plus docetaxel for advanced non-small cell lung cancer","volume":"112","author":"Paz-Ares","year":"2017","journal-title":"Lung Cancer"},{"issue":"25","key":"10.1016\/j.jaccao.2023.05.008_bib72","doi-asserted-by":"crossref","first-page":"2385","DOI":"10.1056\/NEJMoa1214886","article-title":"Crizotinib versus chemotherapy in advanced ALK-positive lung cancer","volume":"368","author":"Shaw","year":"2013","journal-title":"N\u00a0Engl J Med"},{"issue":"10","key":"10.1016\/j.jaccao.2023.05.008_bib73","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1016\/S1470-2045(14)70330-4","article-title":"FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial","volume":"15","author":"Heinemann","year":"2014","journal-title":"Lancet Oncol"},{"issue":"23","key":"10.1016\/j.jaccao.2023.05.008_bib74","doi-asserted-by":"crossref","first-page":"2392","DOI":"10.1001\/jama.2017.7105","article-title":"Effect of first-line chemotherapy combined with cetuximab or bevacizumab on overall survival in patients with KRAS wild-type advanced or metastatic colorectal cancer: a randomized clinical trial","volume":"317","author":"Venook","year":"2017","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.jaccao.2023.05.008_bib75","first-page":"46","article-title":"Options for second-line treatment in metastatic colorectal cancer","volume":"14","author":"Lee","year":"2016","journal-title":"Clin Adv Hematol Oncol"},{"issue":"18","key":"10.1016\/j.jaccao.2023.05.008_bib76","doi-asserted-by":"crossref","first-page":"4506","DOI":"10.3390\/cancers13184506","article-title":"Tackling refractory metastatic colorectal cancer: future perspectives","volume":"13","author":"Personeni","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"2","key":"10.1016\/j.jaccao.2023.05.008_bib77","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1056\/NEJMoa1903835","article-title":"Enzalutamide with standard first-line therapy in metastatic prostate cancer","volume":"381","author":"Davis","year":"2019","journal-title":"N\u00a0Engl J Med"},{"issue":"5","key":"10.1016\/j.jaccao.2023.05.008_bib78","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1056\/NEJMoa1405095","article-title":"Enzalutamide in metastatic prostate cancer before chemotherapy","volume":"371","author":"Beer","year":"2014","journal-title":"N\u00a0Engl J Med"},{"issue":"22","key":"10.1016\/j.jaccao.2023.05.008_bib79","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1056\/NEJMoa1911440","article-title":"Olaparib for metastatic castration-resistant prostate cancer","volume":"382","author":"de Bono","year":"2020","journal-title":"N\u00a0Engl J Med"},{"issue":"suppl","key":"10.1016\/j.jaccao.2023.05.008_bib80","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1200\/JCO.2021.39.15_suppl.1001","article-title":"Updated overall survival (OS) results from the phase III MONALEESA-3 trial of postmenopausal patients (pts) with HR+\/HER2- advanced breast cancer (ABC) treated with fulvestrant (FUL) \u00b1 ribociclib (RIB)","volume":"39","author":"Slamon","year":"2021","journal-title":"J\u00a0Clin Oncol"},{"issue":"1","key":"10.1016\/j.jaccao.2023.05.008_bib81","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1001\/jamaoncol.2019.4782","article-title":"The Effect of abemaciclib plus fulvestrant on overall survival in hormone receptor-positive, ERBB2-negative breast cancer that progressed on endocrine therapy-MONARCH 2: a randomized clinical trial","volume":"6","author":"Sledge","year":"2020","journal-title":"JAMA Oncol"},{"issue":"20","key":"10.1016\/j.jaccao.2023.05.008_bib82","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1056\/NEJMoa1813904","article-title":"Alpelisib for PIK3CA-mutated, hormone receptor-positive advanced breast cancer","volume":"380","author":"Andre","year":"2019","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"10.1016\/j.jaccao.2023.05.008_bib83","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJMoa2203690","article-title":"Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer","volume":"387","author":"Modi","year":"2022","journal-title":"N\u00a0Engl J Med"},{"issue":"4","key":"10.1016\/j.jaccao.2023.05.008_bib84","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/S1470-2045(19)30863-0","article-title":"Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study","volume":"21","author":"Swain","year":"2020","journal-title":"Lancet Oncol"},{"issue":"6","key":"10.1016\/j.jaccao.2023.05.008_bib85","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1016\/S1470-2045(17)30312-1","article-title":"Trastuzumab emtansine versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer (EMILIA): a descriptive analysis of final overall survival results from a randomised, open-label, phase 3 trial","volume":"18","author":"Dieras","year":"2017","journal-title":"Lancet Oncol"},{"issue":"12","key":"10.1016\/j.jaccao.2023.05.008_bib86","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1056\/NEJMoa2115022","article-title":"Trastuzumab deruxtecan versus trastuzumab emtansine for breast cancer","volume":"386","author":"Cortes","year":"2022","journal-title":"N\u00a0Engl J Med"},{"issue":"4","key":"10.1016\/j.jaccao.2023.05.008_bib87","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1158\/2326-6066.CIR-13-0127","article-title":"PD-L1 expression in triple-negative breast cancer","volume":"2","author":"Mittendorf","year":"2014","journal-title":"Cancer Immunol Res"},{"issue":"3","key":"10.1016\/j.jaccao.2023.05.008_bib88","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1056\/NEJMoa2202809","article-title":"Pembrolizumab plus chemotherapy in advanced triple-negative breast cancer","volume":"387","author":"Cortes","year":"2022","journal-title":"N\u00a0Engl J Med"},{"issue":"2","key":"10.1016\/j.jaccao.2023.05.008_bib89","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2022.100409","article-title":"Major advancements in metastatic breast cancer treatment: when expanding options means prolonging survival","volume":"7","author":"Miglietta","year":"2022","journal-title":"ESMO Open"},{"issue":"11","key":"10.1016\/j.jaccao.2023.05.008_bib90","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1038\/bmt.2015.165","article-title":"Patient age, remission status and HCT-CI in a combined score are prognostic for patients with AML undergoing allogeneic hematopoietic cell transplantation in CR1 and CR2","volume":"50","author":"Michelis","year":"2015","journal-title":"Bone Marrow Transplant"},{"issue":"10","key":"10.1016\/j.jaccao.2023.05.008_bib91","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1200\/JCO.2011.40.5977","article-title":"Curability of patients with acute myeloid leukemia who did not undergo transplantation in first remission","volume":"31","author":"Burnett","year":"2013","journal-title":"J\u00a0Clin Oncol"},{"issue":"9","key":"10.1016\/j.jaccao.2023.05.008_bib92","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1016\/S1470-2045(15)00201-6","article-title":"Vosaroxin plus cytarabine versus placebo plus cytarabine in patients with first relapsed or refractory acute myeloid leukaemia (VALOR): a randomised, controlled, double-blind, multinational, phase 3 study","volume":"16","author":"Ravandi","year":"2015","journal-title":"Lancet Oncol"},{"issue":"15","key":"10.1016\/j.jaccao.2023.05.008_bib93","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1200\/JCO.18.01600","article-title":"Venetoclax combined with low-dose cytarabine for previously untreated patients with acute myeloid leukemia: results from a phase Ib\/II study","volume":"37","author":"Wei","year":"2019","journal-title":"J\u00a0Clin Oncol"},{"issue":"6","key":"10.1016\/j.jaccao.2023.05.008_bib94","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1038\/bmt.2008.180","article-title":"Impact of early relapse after auto-SCT for multiple myeloma","volume":"42","author":"Kumar","year":"2008","journal-title":"Bone Marrow Transplant"},{"issue":"8","key":"10.1016\/j.jaccao.2023.05.008_bib95","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1056\/NEJMoa1903455","article-title":"Oral selinexor-dexamethasone for triple-class refractory multiple myeloma","volume":"381","author":"Chari","year":"2019","journal-title":"N\u00a0Engl J Med"}],"container-title":["JACC: CardioOncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666087323001679?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666087323001679?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T18:56:23Z","timestamp":1762973783000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666087323001679"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8]]},"references-count":95,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,8]]}},"alternative-id":["S2666087323001679"],"URL":"https:\/\/doi.org\/10.1016\/j.jaccao.2023.05.008","relation":{},"ISSN":["2666-0873"],"issn-type":[{"value":"2666-0873","type":"print"}],"subject":[],"published":{"date-parts":[[2023,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cardiac Interventions in Patients With Active, Advanced Solid and Hematologic\u00a0Malignancies","name":"articletitle","label":"Article Title"},{"value":"JACC: CardioOncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaccao.2023.05.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier on behalf of the American College of Cardiology Foundation.","name":"copyright","label":"Copyright"}]}}